During our research, we identified 126 vascular disrupting agents that are being developed by close to 32 industry players and organizations for the treatment of different disease indications.

As can be observed in the figure, majority (40%) of the companies engaged in this domain are small firms (less than 50 employees). This is followed by large (17%), and very large (27%) companies. Examples of very large players include (in alphabetical order, no specific selection criteria) AbbVie, Celgene, Mayo Clinic, Novartis, Sanofi Genzyme, Takeda, Teva Pharmaceutical Industries and The University of Texas MD Anderson Cancer Center. Although the efforts for developing vascular disrupting agents have been undertaken by various players across the globe, majority (54%) of them are based in North America.

For additional details, please visit –

As can be observed in the following figure, majority of the vascular disrupting agents are currently in the phase II (52%) and phase I (36%) of clinical studies, while 7% are in phase III of clinical development or have been marketed. It is worth highlighting that vascular disrupting agent Padeliporfin (Steba biotech) has been marketed for prostate cancer. Other VDAs namely (arranged in alphabetical order) Bavituximab, Icaritin, NGR-TNF, Ofranergene obadenovec, Padeliporfin and Plinabulin, are currently in phase III of development for different indications and are likely to enter the market in the near future. Further, the phase II clinical development are mainly focused on the treatment of lung cancer and colorectal cancer.

Leave a Reply